TG Therapeutics TGTX Stock
TG Therapeutics Price Chart
TG Therapeutics TGTX Financial and Trading Overview
| TG Therapeutics stock price | 56.41 USD |
| Previous Close | 57.12 USD |
| Open | 56.7 USD |
| Bid | 47.05 USD x 100 |
| Ask | 63.78 USD x 100 |
| Day's Range | 54 - 56.93 USD |
| 52 Week Range | 25.28 - 59.3 USD |
| Volume | 1.85M USD |
| Avg. Volume | 2.4M USD |
| Market Cap | 8.42B USD |
| Beta (5Y Monthly) | 1.597 |
| PE Ratio (TTM) | 19.234266 |
| EPS (TTM) | 2.94 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.63 USD |
TGTX Valuation Measures
| Enterprise Value | 8.04B USD |
| Trailing P/E | 19.234266 |
| Forward P/E | 17.100845 |
| PEG Ratio (5 yr expected) | 1.61 |
| Price/Sales (ttm) | 12.024188 |
| Price/Book (mrq) | 13.371415 |
| Enterprise Value/Revenue | 11.473 |
| Enterprise Value/EBITDA | 53.719 |
Trading Information
TG Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.597 |
| 52-Week Change | 46.76% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 59.3 USD |
| 52 Week Low | 25.28 USD |
| 50-Day Moving Average | 45.33 USD |
| 200-Day Moving Average | 35.27 USD |
TGTX Share Statistics
| Avg. Volume (3 month) | 2.4M USD |
| Avg. Daily Volume (10-Days) | 2.61M USD |
| Shares Outstanding | 153.08M |
| Float | 135.1M |
| Short Ratio | 9.8 |
| % Held by Insiders | 7.47% |
| % Held by Institutions | 70.26% |
| Shares Short | 30.17M |
| Short % of Float | 28.48% |
| Short % of Shares Outstanding | 19.70% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 100:5625 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 65.95% |
| Operating Margin (ttm) | 16.98% |
| Gross Margin | 83.05% |
| EBITDA Margin | 21.35% |
Management Effectiveness
| Return on Assets (ttm) | 8.55% |
| Return on Equity (ttm) | 112.59% |
Income Statement
| Revenue (ttm) | 700.35M USD |
| Revenue Per Share (ttm) | 4.87 USD |
| Quarterly Revenue Growth (yoy) | 69.59% |
| Gross Profit (ttm) | 581.67M USD |
| EBITDA | 149.58M USD |
| Net Income Avi to Common (ttm) | 461.9M USD |
| Diluted EPS (ttm) | 2.86 |
| Quarterly Earnings Growth (yoy) | 290.89% |
Balance Sheet
| Total Cash (mrq) | 514.43M USD |
| Total Cash Per Share (mrq) | 3.63 USD |
| Total Debt (mrq) | 753.56M USD |
| Total Debt/Equity (mrq) | 129.23 USD |
| Current Ratio (mrq) | 5.809 |
| Book Value Per Share (mrq) | 4.114 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13951000 USD |
| Levered Free Cash Flow (ttm) | -30164876 USD |
Profile of TG Therapeutics
| Country | United States |
| State | NC |
| City | Morrisville |
| Address | 3020 Carrington Mill Blvd. |
| ZIP | 27560 |
| Phone | 212 554 4484 |
| Website | https://www.tgtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 399 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Q&A For TG Therapeutics Stock
What is a current TGTX stock price?
TG Therapeutics TGTX stock price today per share is 56.41 USD.
How to purchase TG Therapeutics stock?
You can buy TGTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TG Therapeutics?
The stock symbol or ticker of TG Therapeutics is TGTX.
Which industry does the TG Therapeutics company belong to?
The TG Therapeutics industry is Biotechnology.
How many shares does TG Therapeutics have in circulation?
The max supply of TG Therapeutics shares is 153.08M.
What is TG Therapeutics Price to Earnings Ratio (PE Ratio)?
TG Therapeutics PE Ratio is 19.18707500 now.
What was TG Therapeutics earnings per share over the trailing 12 months (TTM)?
TG Therapeutics EPS is 2.94 USD over the trailing 12 months.
Which sector does the TG Therapeutics company belong to?
The TG Therapeutics sector is Healthcare.
TG Therapeutics TGTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32406.63 USD — |
+0.62
|
— — | 32125.24 USD — | 32465.34 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3179.98 USD — |
+0.45
|
— — | 3165.92 USD — | 3192.38 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
140.4 USD — |
+0.07
|
— — | 138.5 USD — | 141.42 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4030.44 USD — |
-0.31
|
— — | 3987.18 USD — | 4063.78 USD — | — - | — — |
- {{ link.label }} {{link}}